The USFDA issued six observations to Granules India’s Gagillapur facility in Hyderabad after an inspection between August 26 and September 6. The company is committed to addressing these issues promptly and will submit its response within the stipulated time frame. Following this news, Granules India’s stock fell by over 16% on the BSE.
Related Posts
IAF’s Sukhoi-30 MKI fighter jets: India, Russia exploring joint production of Sukhoi engine
India and Russia are considering joint production of AL-31FP engines for the Su-30MKI fighters, following discussions during DK Sunil’s visit to Russia. This follows HAL’s […]
Swiggy submits revised IPO draft papers to Sebi, aims to raise over Rs 10,000 crore
Swiggy has submitted updated draft papers to Sebi for its anticipated IPO, which includes a fresh issue worth Rs 3,750 crore and an offer-for-sale of […]
Catch-up: Amazon goes all in on AI
At its re:Invent conference, Amazon Web Services (AWS) launched new AI models and chips, including the Trainium2 and Nova, to compete with rivals like Microsoft […]